Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-05-12
1997-02-18
Sayala, Chhaya D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 12, 514 21, 530327, 424 942, A61K 3816
Patent
active
056041985
ABSTRACT:
A method is provided to enhance the ability of a neurologically active compound to penetrate the blood nerve barrier (BNB) or blood brain barrier (BBB), by administration of a conjugate comprising the neurologically active compound linked to a carrier molecule that has been shown to have a substantial permeability coefficient across the BNB and BBB.
REFERENCES:
patent: 3903262 (1975-09-01), Pappenhagen et al.
patent: 4863730 (1989-09-01), Karpas
patent: 5260308 (1993-11-01), Poduslo et al.
patent: 5304632 (1994-04-01), Vaudry et al.
patent: 5360610 (1994-11-01), Tice et al.
patent: 5442043 (1995-08-01), Fukuta et al.
Meijer, D. F. K. et al, Antiviral Res., vol. 18, pp. 215-258, 1992.
Fiani, Maria et al., TIBTECH, vol. 7, pp. 57-61, Mar. 1989.
Pardridge, William TIBTECH, vol. 12, pp. 239-245, Jun. 1994.
Patel N. J. et al., Diabetologia, vol. 34, pp. 78-80, 1991.
Zlohovic, J Controlled Res., vol. 13, pp. 185-201, 1990.
Stern et al., Arch. int. Pharmacodyn., vol. 202, pp. 259-262, 1973.
Andersson et al., "Synthesis of oligosaccharides with oligoethylene glycol spacers and their conversion into glycoconjugates using N,N, N',N"tetramethyl (succinimido)uronium tetrafluoroborate as coupling reagent," Glycoconjugate Journal, 10, 197 (1993).
Barbin et al., "Purification of the Chick Eye Ciliary Neuronotrophic Factor," J. Neurochem., 43, 1468 (1984).
Barde et al., "Purification of a new neurotrophic factor from mammalian brain," EMBO J., 1, 549 (1982).
J. Barnett et al., "Human Nerve Growth Factor Obtained from a Baculovirus Expression System Has Potent in Vitro and in Vivo Neurotrophic Activity," Exp. Neurol., 110:11 (1990).
D. Baskin et al., "Insulin in the Brain," Ann. Rev. Physiol., 49, 335 (1987).
D. Baskin et al., "Insulin and Insulin-Like Growth FActors in the CNS," Trends in Neurosciences, 11, 107 (1988).
S. Berkman et al., "Clinical Uses of Intravenous Immunoglobulins," Ann. Int. Med., 112:278 (1990).
Bovin et al., "Synthesis of polymeric neoglycoconjugates based on N-Substituted polyacrylamides," Glycoconjugate Journal, 10, 142 (1993).
M. Brownlee et al., "Trapped Immunoglobulins on Peripheral Nerve Myeline from Patients with Diabetes Mellitus," Diabetes, 35:999 (1986).
Bunn et al., "Reaction of Monosaccharides with Proteins: Possible Evolutionary Significance," 213, 222 (1991).
D. Cook et al., "High-dose Intravenous Immunoglobulin in the Treatment of Demyelinating Neuropathy Associated with Monoclonal Gammopathy," Neurology, 40:212 (1990).
L. Curtiss et al., "A Novel Method for Generating Region-Specific Monoclonal Antibodies to Modified Proteins," J. Clin. Invest., 72:1427 (Oct. 1983).
W. Fischer et al., "Amelioration of Cholineragic Neuron Atrophy and Spatial Memory Impairment in Aged Rats for Nerve Growth Factor," Nature, 329:65 (1987).
Hefti et al., "Function of Neurotrophic Factors in the Adult and Aging Brain and Their Possible Use in the Treatment of Neurodegenerative Diseases," Neurobiology of Aging, 10, 515 (1989).
A. Karpas et al., "Effects of Passive Immunization in Patients with the Acquired Immunodeficiency Syndrome-Related Complex and Acquired Immunodeficiency Syndrome," PNAS USA, 85:9234 (1988).
Knusel et al., "Brain-derived Neurotrophic Factor Administration Protects Basal Forebrain Cholinergic but Not Nigral Dopaminergic Neurons from Degenerative Changes after Axotomy in the Adult Rat Brain," J. Neurosci. Res., 12(11):4391 (1992).
Koliatsos et al., "Evidence That Brain-Derived Neurotrophic Factor is a Trophic Factor for Motor Neurons In Vivo," Neuron, 10, 359 (1993).
A. LeBlanc et al., "Regulation of Apolipoprotein E. Gene Expression After Injury of the Rat Sciatic Nerve," J. Neuroscience Res., 25:162 (1990).
P. Lipsky et al., "Intravenous Immunoglobulin. Prevention and Treatment of Disease," JAMA, 264:3189 (1990).
Louis et al., "CNTF Protection of Oligodendrocytes Against Natural and Tumor Necrosis Factor-Induced Death," Science, 259, 689 (1993).
Meakin et al., "The nerve growth factor family of receptors," TINS, 15 323 (1992).
J. Poduslo et al., "Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy," PNAS USA, 89, 2218 (1992).
J. Poduslo, "Glycoprotein Molecular-Weight Estimation Using Sodium Dodecyl Sulfate-Pore Gradient Electrophoresis: Comparison of the Tris-Glycine and Tris-Borate-EDTA Buffer Systems," Anal. Biochem., 114, 131 (1981).
J. Poduslo et al., "Altered Blood-Nerve Barrier in Experimental Lead Neuropathy Assessed by Changes in Endoneurial Albumin Concentration," J. Neurosci., 2, 1507 (1982).
J. Poduslo et al., "Mammalian Endoneurial Fluid: Collection and Protein Analysis from Normal and Crushed Nerves," Brain Res., 332, 91 (1985).
J. Poduslo et al., "Increase in Albumin IgG, and IgM Blood-Nerve Barrier Indices in Human Diabetic Neuropathy," PNAS USA, 85:4879 (1988).
Pozsgay, "A method for glycoconjugate synthesis," Glycoconjugate Journal, 10, 133 (1993).
E. Rechthand et al., "Regulation of the Microenvironment of Peripheral Nerve: Role of the Blood-Nerve Barrier," Progress in Neurobiology, 28:303 (1987).
M. Scwhartz et al., "Kinetics and Specificity of Insulin Uptake from Plasma into Cerebrospinal Fluid," Am. J. Physiol., 259:E378 (1990).
Sendtner et al., "Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section," Nature, 360, 757 (1992).
N. Shaklai et al., "Nonenzymatic Glyosylation of Human Serum Albumin Alters its Conformation and Function," J. Biol. Chem., 259:3812 (1984).
P. Smith et al., "Measurement of Protein Using Bicinchoninic Acid," Anal. Biochem., 150, 76 (1985).
Smith et al, "Nonenzymic Glycation of Albumin by Acyl Glucuronides In Vitro," Biochemical Pharmacology, 44, 1661 (1992).
Swamy et al., "Glycation Mediated Lens Crystallin Aggregation and Crosslinking by Various Sugar Phosphates In Vitro" Exp. Eye Res., 56, 177 (1993).
Szwergold et al., "Identification of Fructose 3-Phosphate in the Lens of Diabetic Rats," Science, 247 451 (1990).
J. Tarsio et al., "Nonenzymatic Glycation of Fibronectin and Alterations in the Molecular Association of Cell Matrix and Basement Membrane Components in Diabetes Mellitus," Diabetes, 34, 477 (1985).
J. Tarsio et al., "Decreased Interaction of Fibronectin, Type IV Collagen and Heparin Due to Nonenzymatic Glycation. Implications for Diabetes Mellitus," Biochemistry, 26, 1014 (1987).
P. Van Doorn et al., "On the Mechanism of High-Dose Intravenous Immunoglobulin Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy," J. Neuroimmunol., 29:57 (1990).
Watters et al., "Purification of Ciliary Neurotrophic Factor from Bovine Heart," J. Neurochem., 49, 705 (1987).
A. Weerasuriya et al., "Blood-Nerve Transfer of Albumin and Its Implications for the Endoneurial Microenvironment," Brain Res., 494, 114 (1989).
Wong et al., "Synthetic glycosylation of peptides using unprotected saccharide .beta.-glycosylamines," Glycoconjugate Journal, 10, 227 (1993).
Yan et al., "Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death," Nature, 360, 753 (1992).
Curran Geoffrey L.
Poduslo Joseph F.
LandOfFree
Method to enhance permeability of the blood/brain blood/nerve ba does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to enhance permeability of the blood/brain blood/nerve ba, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to enhance permeability of the blood/brain blood/nerve ba will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1602538